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Testosteronetherapyinmenandwomenresultsindecreasedhigh-densitylipoproteincholesterol(HDL)andincreasedlow-density
lipoprotein cholesterol (LDL). We sought to determine whether testosterone therapy has this same eﬀect on lipid parameters and
adipocyte hormones in female-to-male (FTM) transsexuals. Twelve FTM transsexuals provided a fasting lipid proﬁle including
serum total cholesterol, HDL, LDL, and triglycerides prior to and after 1 year of testosterone therapy (testosterone enanthate
or cypionate 50–125mg IM every two weeks). Subjects experienced a signiﬁcant decrease in mean serum HDL (52 ± 11 to
40 ± 7mg/dL) (P<. 001). The mean LDL (P = .316), triglyceride (P = .910), and total cholesterol (P = .769) levels remained
unchanged. In a subset of subjects, we measured serum leptin levels which were reduced by 25% but did not reach statistical
signiﬁcance (P = .181) while resistin levels remained unchanged. We conclude that testosterone therapy in FTM transsexuals can
promote an increased atherogenic lipid proﬁle by lowering HDL and possibly reduce serum leptin levels. However, long-term
studies are needed to determine whether decreases in HDL result in adverse cardiovascular outcomes.
1.Introduction
Transsexualism is a medical condition characterized by
genderdysphoriawhichismanagedwithcross-sexhormones
and surgery to align an individual’s physical appearance with
theirgenderorientation[1,2].Female-to-male(FTM)trans-
sexuals take testosterone to change into a more masculine
phenotype. Current guidelines remain uncertain about long
eﬀects of testosterone therapy on cardiovascular outcomes
due to lack of long-term studies and suggest risk factors
including lipids to be managed individually [1]. A recent
meta-analysis of ten studies of testosterone therapy in FTM
transsexuals by Elamin et al. demonstrated increased serum
triglycerides (TG) and reduced high-density lipoprotein
(HDL) concentrations. However, the data remained unclear
about testosterone’s eﬀects on other lipid fractions and
blood pressure [3]. Other studies not examined in the meta-
analysis by Elamin et al. have demonstrated increased total
cholesterol (TC) [4] and low-density lipoprotein (LDL) lev-
els [4, 5] in FTM transsexuals receiving testosterone therapy.
Similarly, 17 FTM transsexuals treated with intramuscular
injections of long acting testosterone undecanonate for 36
months demonstrated a decrease in TC and LDL without
eﬀecting triglyceride and HDL levels [6].
Gooren et al. [7] suggested that an increased atherogenic
lipid proﬁle can be a result increased weight and visceral
fat after testosterone therapy in FTM transsexuals [8]. This
changed adiposity pattern can lead to diﬀerential adipocyte
hormone secretion [9, 10]. However, studies evaluating the
eﬀectoftestosteronetherapyonadipocytehormonesinFTM
transsexuals are minimal and available data remain incon-
clusive. While Elbers et al. [11] reported supraphysiological
doses of testosterone in FTM to reduce leptin levels; others
have failed to conﬁrm this ﬁnding [12]. Similarly, the eﬀect
of supraphysiologic doses of testosterone administration on
resistin still remains to be understood though endogenous2 International Journal of Endocrinology
androgens in Polycystic Ovarian Syndrome (PCOS) have
been shown to cause elevated resistin levels after controlling
for body mass [13].
We hypothesized that supraphysiologic (male replace-
ment) doses of testosterone in FTM transsexuals (genetic
females) would lead to a more atherogenic lipid proﬁle
and increase markers of insulin resistance. Our prospective
clinical trial evaluated changes in the lipid proﬁle and
the adipokines, resistin and leptin, in FTM transsexuals
before and after treatment with male-replacement doses of
testosterone.
2. Methods
The study was approved by the Boston University School of
Medicine IRB and was conducted at the Boston University
General Clinical Research Clinic (GCRC).
2.1. Study Subjects. Subjects were recruited from the
endocrinology clinics at Boston University as previously
described [14]. Brieﬂy, all subjects were genetic females who
weredeemedtohavegenderidentitydisorderbytheirmental
health provider and were recommended for treatment with
testosterone therapy. For this study, we evaluated subjects
who had not previously received testosterone therapy and
were analyzed prior to sex reversal surgery.
2.2. Procedures. We prospectively monitored the serum
lipoprotein proﬁle of 12 FTM transsexuals who were started
on supraphysiologic doses of testosterone esters, cypionate,
or enanthate (supraphysiologic for a female but replacement
levels for a male) (50–125mg every two weeks to attain male
physiological levels of serum testosterone), for 12 months.
Subjects provided a fasting blood sample for TC, LDL,
LDL, HDL, and triglyceride measurements at baseline and
1 year after initiating testosterone therapy. Due to sample
availability,wemeasuredserumresistinandleptinlevelsonly
in a subset of subjects (n = 5) at baseline and at least 6 to 12
months after initiation of testosterone therapy.
Cholesterol, glucose, hematocrit, and total testosterone
were measured by a commercial laboratory (Quest Diag-
nostics, (San Juan Capistrano, CA). The resistin and leptin
levels were drawn at the same time as the testosterone and
at the “trough” level of testosterone. Leptin and Resistin
weremeasuredusing commerciallyavailableELISAkits from
ALPCO Diagnostics (Salem, New Hampshire). The intra-
and inter-assay CVs for the Leptin ELISA were 3.7%–5.5%
and 5.8%–6.9%, respectively. The intra- and inter-assay CVs
for the resistin ELISA were 2.9%–5.2% and 4.2%–7.2%,
respectively.
2.3. Statistical Analysis. The results were represented as
means ± SEM. The data were analyzed using Microsoft Excel
(Oﬃce2000)andSigmaStatVersion3.0.Diﬀerencesinlevels
of serum lipid levels were evaluated by using paired t-test.
Diﬀerences in serum resistin and leptin levels were evaluated
by mean percentage change from baseline.
Table 1: Demographic background of female to male transsexuals
prior to the initiation of testosterone therapy (n = 12).
N = 12
Age (years) 29 ± 9
Race (n)
African/Caucasian/Hispanic 1/10/1
Smokers (n)4
3. Results
3.1.SubjectDemographics. Table 1 demonstratesthebaseline
demographics of the study population. The mean age of our
subjects was 29 ± 9 years. Ten out of 12 subjects identiﬁed
themselves as of Caucasian ethnicity, while 1 each were
fromHispanicandAfricanAmericanethnicity.Foursubjects
i d e n t i ﬁ e dt h e m s e l v e sa sa c t i v es m o k e r s .
3.2. Changes in Clinical and Biochemical Markers in Response
to Testosterone. As expected, serum testosterone values
increased after the initiation of testosterone therapy (P<
.001) (Table 2). The increase in testosterone was accompa-
nied by an increase in hematocrit (P<. 001) (Table 2).
We did not observe any changes in the clinical param-
eters of body mass index and mean arterial pressure or
in the biochemical parameters of the liver transaminases
(SGOT/SGPT) or platelet count (Table 2).
3.3. Changes in Lipid Parameters. We observed a signiﬁcant
decrease in high-density lipoprotein (HDL) cholesterol (P<
.001) but no signiﬁcant changes in the other lipid parameters
such as low-density lipoprotein (LDL), total cholesterol, or
triglycerides (Table 2). The serum resistin and leptin (n = 5)
remainedunchangedfrom10.3 ±2.1to9.6 ±2.2ng/dL(P =
.679) and 31.2 ± 29.5 to 19.1 ± 17.5ng/dL (a 25% reduction,
P = .181), respectively (Table 2).
4. Discussion
Ourstudydemonstratedasigniﬁcantdecreaseintheconcen-
tration of HDL after 1 year of testosterone therapy in FTM
transsexuals, as previously reported by other studies [3, 4,
15]. The serum LDL, TG, and TC did not show a signiﬁcant
change. The leptin and resistin levels did not demonstrate a
signiﬁcant change, owing to the small number of subjects.
There was no increase in mean arterial blood pressure or
change in BMI after two years of therapy. Liver enzymes and
fasting blood glucose levels remained unchanged, while as
expected there was a rise in hematocrit.
Several studies have examined the eﬀects of testosterone
on lipid concentrations in females and in FTM transsexuals.
Goh et al. demonstrated a decrease in HDL and an increase
in LDL, TG, and TC levels after long-term testosterone
therapy in women [4]. Mueller et al. demonstrated an
increased serum TG concentration and a decreased HDL
concentration without any change in LDL in FTM sub-
jects treated with testosterone [15]. Similarly, Elbers et al.International Journal of Endocrinology 3
Table 2: Biochemical changes in response to 12 months of testos-
terone therapy in female-to-male transsexuals, including changes in
lipidproﬁleandmarkersofinsulinresistance.Mean ±SEM,N = 12
unless speciﬁed.
Prior to Testosterone 12 months P-value
Body Mass
Index (BMI)
(kg/m2)
27.5 ±5.22 7 .6 ±3.9 .47
Mean Arterial
Pressure (MAP
(mm Hg)
87 ±14 91 ±16 .16
Serum Glutamic
Oxaloacetic
Transaminase
(SGOT) (IU/L)
21 ±52 5 ±7 .22
Serum
Glutamate
Pyruvate
Transaminase
(SGPT) (IU/L)
19 ±72 4 ±10 .22
Serum Total
Testosterone
(nmol/L)
3.4 ±3.03 4 .6 ±8.5 <.001
Hematocrit (%) 40 ±24 5 ±5 <.001
Platelets
(×1000/µL)
282 ±44 266 ±38 .21
High Density
Lipoprotein
(HDL) (mg/dL)
52 ±11 40 ± 7 <.001
Low Density
Lipoprotein
(LDL) (mg/dL)
113 ±22 121 ±29 .32
Total
Cholesterol
(mg/dL)
184 ±26 181 ±34 .77
Triglycerides
(mg/dL)
92 ±72 94 ±41 .91
Leptin (ng/dL) 31.2 ±29.51 9 .1 ±17.5 .18
Resistin (ng/dL) 10.3 ±2.19 .6 ±2.2 .68
Fasting glucose
(mg/dL)
86 ±12 83 ±11 .43
demonstrated a decreased HDL and LDL particle size and
increasedTGconcentrationaftertestosteroneadministration
in FTM transsexuals [8]. In contrast, Jacobeit et al. [16]
demonstrated that testosterone therapy in FTM transsexuals
resulted in a statistically signiﬁcant decrease in the level of
TC and LDL, with no change in HDL. A recent meta-analysis
oftestosteronetherapyinFTMtranssexualsdemonstratedan
increaseinTGanddecreaseinHDLinFTMtranssexuals[3].
Ofimportance,theincreaseinTGlevelswasmoresigniﬁcant
in studies which had longer followup times [3]. Our study
is consistent with the majority of studies that demonstrate
a reduced HDL level but we were unable to demonstrate a
change in TG levels likely due to the short-term nature of
our study.
Despite seemingly adverse changes in the lipid pro-
ﬁle from testosterone administration in FTM transsexuals,
testosterone administration has not been associated with
increased cardiovascular morbidity or mortality in FTM
transsexuals [3, 7]. Therefore, in a subset of our patients,
we investigated eﬀects of testosterone supplementation on
adipocyte hormones that are putative cardiovascular risk
factors.Leptinisanadipocytehormonethatsignalsreceptors
in hypothalamus to decrease food intake and stimulates
energy expenditure [17]. Studies have demonstrated leptin
to be an independent risk factor for stroke and myocardial
infarction after controlling for obesity status [18, 19]. Leptin
administration has been reported to raise serum TG, LDL,
a n dT Cl e v e l s[ 20]. Supraphysiological doses of testosterone
in FTM transsexuals have been reported to reduce plasma
leptin concentration [11, 21]. However, Resmini et al. [12]
reported a strong interindividual variability in response of
plasma leptin levels to testosterone therapy and, hence, failed
to show a signiﬁcant posttreatment change. Similarly, in a
subset of our subjects, we found a 25% decrease in plasma
leptin concentration with testosterone therapy which did
not reach statistical signiﬁcance likely to the small number
of subjects evaluated. Therefore, we can only conclude that
larger and more long-term studies need to be conducted to
conﬁrm the eﬀects of testosterone on leptin concentrations
in FTM transsexuals.
Resistin is an adipocytokine that is associated with
obesity-mediated insulin resistance [22] and increased car-
diovascular risk [23]. We are not aware of a previously
published study to evaluate testosterone therapy on resistin
concentrations in FTM transsexuals. Data from females with
elevated endogenous androgen levels as occurring in PCOS
have attempted to evaluate the relationship between resistin
andandrogenconcentrations.Seowetal.foundnodiﬀerence
in serum resistin levels in patients with and without PCOS
and there was no correlation between serum resistin and
testosterone levels [24]. However in contrast, Carmina et
al. reported elevated plasma resistin levels in PCOS patients
[13]. Finally, Yilmaz et al. [25] reported that plasma resistin
levels were not associated with androgen concentrations in
women with PCOS [25]. In summary, few studies have
evaluated the relationship between endogenous testosterone
levels or testosterone therapy on resistin concentrations. Our
study did not demonstrate any signiﬁcant diﬀerences in the
resistin levels after administration of testosterone in FTM
transsexuals.
5. Conclusion
Testosterone therapy in FTM transsexuals results in a more
atherogenic lipid proﬁle by signiﬁcantly decreasing HDL.
Although limited by the population size, our preliminary
study found that initiation of testosterone therapy in female-
to-male (FTM) transsexuals may lower plasma leptin levels.
Long-term studies are needed to monitor cardiovascular
events in FTM transsexuals on testosterone therapy to
determine if these changes in the lipid proﬁle and adipocyte
hormones translate into increased cardiovascular events.4 International Journal of Endocrinology
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